Business Wire

H2SITE Raises 12,5M€ to Scale Membrane Reactor Breakthrough Technology

30.6.2022 09:00:00 EEST | Business Wire | Press release

Share

H2SITE, a deep-tech pioneer in on-site hydrogen (H2) production, announced today that it has raised 12,5 M€ in a Series A funding round led by Breakthrough Energy Ventures (BEV), with participation from Equinor Ventures, ENGIE New Ventures, TECNALIA and institutional investors from the Basque Country (Capital Riesgo País Vasco (EZTEN FCR) and Seed Capital Bizkaia (SCB)).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005760/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Membrane bundle for ammonia cracking reactor (Photo: H2SITE)

The funding will accelerate the scale up of H2SITE's integrated membrane reactor and membrane separation technologies to obtain fuel cell purity hydrogen from ammonia or methanol cracking, or enable hydrogen transportation in existing natural gas infrastructure. H2SITE will also increase its membrane manufacturing capabilities, operating a world unique membrane manufacturing plant in the North of Spain.

“While much focus is given to hydrogen generation cost reduction, less attention is given to reduction of hydrogen transport cost. Transporting hydrogen is a complex task, it being a small molecule that is difficult to contain. The current compression, storage, decompression, and transport solutions are both economically and environmentally inefficient”, says Andrés Galnares, H2SITE’s CEO.

TECNALIA, Spain’s largest private research center, and the Technical University of Eindhoven realized that 13 years ago and developed the advanced membrane reactors. They combine special membranes with one-process-step reactors to produce onsite, low-cost renewable hydrogen. ENGIE’s R&D entity CRIGEN contributed to the development of the commercial version of the reactor. Intellectual Property was transferred into the newly created H2SITE to commercialize the technology.

H2SITE has since developed these onsite hydrogen generation units. Double skin inorganic membranes with long lifespan, integrated into process units can both crack hydrogen carriers and separate the hydrogen from blends in natural gas infrastructure or purify it in dedicated hydrogen infrastructure.

Hydrogen is a promising pathway to decarbonize many parts of the economy but transporting it remains one of the biggest challenges. H2SITE has developed a solution that solves the transportation issue and will change the game for how quickly hydrogen can be deployed in already established pipelines which in turn could save billions of dollars in infrastructure costs,” said Carmichael Roberts of Breakthrough Energy Ventures.

H2SITE has shown strong commercial traction in 2022 and has recently been awarded projects to transform ammonia into H2 for the bus fleet in Birmingham, England, biogas into H2 for hydrogen refueling stations in Spain and in France, as well as several separation projects from H2 / natural gas blends in the gas transport infrastructure that are under construction.

“As an early investor from the very beginning of H2SITE journey, ENGIE New Ventures showed its commitment to the development of a promising and versatile technology to scale up sustainable and efficient solutions for industry and mobility needs; this support materialized also through ENGIE developing some commercial projects in H2 refueling stations using H2SITE technology,” said Johann Boukhors, Managing Director of ENGIE New Ventures.

According to BNEF’s New Energy Outlook 2021, the “green scenario” will require 1300M tons of H2 to reach net zero. If only 10% will be separated or transported with H2 carriers at an average cost of 0,5USD/kg, the market size in 2050 will be over 50 billion USD/year in 2050. H2SITE makes it possible to have access to these separation costs as of today and will further reduce them in the future.

“Equinor has high ambitions for clean hydrogen and Equinor Ventures invests in technologies that support the development of novel hydrogen value chains,” says Gareth Burns, head of Equinor Ventures. “H2Site has developed innovative technologies enabling the use of existing natural gas infrastructure to bring clean hydrogen to end users. These solutions have a potential for direct application within Equinor’s future hydrogen projects and I look forward to seeing the technology further developed and deployed,” he adds.

“H2SITE is a unique combination of: excellent research, mostly funded by European Commission framework programs resulting in state-of-the-art membrane reactor technology developed by Tecnalia and TUe; a purposeful entrepreneurial “A-Team”; some of the best smart capital in the realm of decarbonization in the World, topped with strong public support from with the participation of the sovereign funds of the Basque region, EZTEN FCR and Biscay region, SCB in the funding round; resulting in a gazelle massively incorporating top talent and anchoring a regional supply chain. This is the type of deep tech venture building endeavor that Tecnalia Ventures fosters, aimed at unfolding the potential Europe has to lead the global decarbonization challenge,” said Asier Rufino, CEO Tecnalia Ventures and H2SITE Chairman.

This investment by BEV-E is much needed. The hydrogen economy needs to take off and I believe investments such as the current one may indeed be one of the triggers we’re waiting for,” said Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth. “Facilitating hydrogen transport will be important to scale-it-up. This shows that public funds can be married with private funds successfully, as happened with BEV-E. Investments in the energy transition must however take place at an even faster pace if we want to succeed in our climate ambition.

Breakthrough Energy Ventures Europe (BEV-E) was established by the European Commission, the European Investment Bank and Breakthrough Energy Ventures to invest in innovative European companies and bring radically new clean energy technologies to the market. It was established to support Europe's best clean energy entrepreneurs whose solutions can deliver significant and lasting reductions in greenhouse gas emissions—H2SITE and this investment in the company is an example of that.

European Investment Bank (EIB) Vice-President Ricardo Mourinho Félix said: “To meet the global climate and energy challenges, we must scale up investment for clean energy technologies. Together with our partners at the European Commission, we are supporting Breakthrough Energy Ventures Europe which is investing in European companies such as H2SITE to find innovative solutions that will put the world on track to net-zero emissions. Transporting green hydrogen from geographies with strong renewable energy resources to demand centres is an important part of the EU Hydrogen and decarbonisation strategy. At the EIB, we will continue to work with our partners and project promoters to support the clean energy transition in Europe and around the world.”

H2SITE is currently hiring in the Bilbao region. To learn more, follow H2SITE on LinkedIn.

About H2SITE

H2SITE is a deep-tech start-up that uses advanced membrane reactor technology to solve the hydrogen transport problem by converting hydrogen carriers with well-known supply chains and separating hydrogen gas blends into fuel cell purity hydrogen.

About Breakthrough Energy Ventures

Founded by Bill Gates and backed by many of the world’s top business leaders, BEV has raised more than $2 billion in committed capital to support cutting-edge companies that are leading the world to net-zero emissions. BEV is a purpose-built investment firm that is seeking to invest, launch and scale global companies that will eliminate GHG emissions throughout the economy as soon as possible. BEV seeks true breakthroughs and is committed to supporting these entrepreneurs and companies by bringing to bear a unique combination of technical, operational, market and policy expertise.

BEV is a part of Breakthrough Energy, a network of investment vehicles, philanthropic programs, policy advocacy and other activities committed to scaling the technologies we need to reach net-zero emissions by 2050. Visit www.breakthroughenergy.org to learn more.

About EQUINOR Ventures

Equinor Ventures is Equinor’s corporate capital venture fund dedicated to investing in attractive and ambitious early phase and growth companies. We believe that the innovation, creativity and agility of start-ups can drive change and transition towards a low carbon future.

About ENGIE New Ventures

ENGIE New Ventures (ENV) is the investment fund of ENGIE, Research & Innovation division, dedicated to innovative climate technology startups and the corporate venture capital arm of ENGIE, the global energy and services provider. ENGIE is committed to lead the energy revolution, towards a more decarbonized, decentralized, and digitized world. ENV makes minority investments in innovative start-ups bringing strategic value to the Group with a focus on both the current ecosystem and on future breakthrough technologies. Since 2014, investments have been made in more than 45 solutions in the cleantech sector. Investment thesis is now focused in particular on renewables, energy efficiency solutions and flexibility, green gases including hydrogen. ENV’s offices are represented in Paris, San Francisco, Singapore, Santiago and Tel Aviv.

About TECNALIA

TECNALIA is the largest applied research and technological development center in Spain, a European benchmark and member of the Basque Research and Technology Alliance. We work with companies and institutions to increase their competitiveness, quality of life of people and achieve sustainable growth. Its main areas of action are digital transformation, smart manufacturing, energy transition, sustainable mobility, urban ecosystem, circular economy and personalized health. (www.tecnalia.com)

Through TECNALIA Ventures, its deep tech venture builder, the center collaborates in the identification and deployment of deep tech business opportunities with commercialization potential, through the development of its technological asset’s incubation acceleration program. (www.tecnaliaventures.com)

About EZTEN FCR

EZTEN FCR is a venture capital fund managed by Gestión de Capital Riesgo del País Vasco, a company belonging to the SPRI Group-Basque Agency for Business Development.

EZTEN FCR invests in innovative Basque companies, especially in the areas of biosciences, advanced manufacturing, and clean energy, in order to promote their development.

About Seed Capital Bizkaia

Public Company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, intended for the administration and management of various financing instruments. Founded in 1989, Seed Capital Bizkaia, during more than 30 years of work, has always made a firm commitment to promoting innovation, social impact and the promotion and regeneration of the business fabric in Bizkaia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact – Andrés Galnares; andres.galnares@h2site.eu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye